Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs)

Transcription

1 Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs) 1

2 Labellised between 2011 & Integrated Cancer Research Sites (SIRICs) were created by the French National Cancer Institute (INCa) between 2011 & 2012 SIRICs implementation aims to offer new operational conditions to cancer research, in order to optimise and accelerate the production of new knowledge and favor its dissemination and applications in cancer care management. INCa (Institut National du Cancer) 2 2

3 To formulate and implement integrated research programmes by: Modifiez les styles du texte du masque Sharing questions and objectives Creating synergies Improving patient management France s Integrated Cancer Research Sites missions Deuxième niveau Troisième niveau To disseminate and transfer research results by: Communicating and transfering results Creating interfaces between health care Quatrième professionals niveau Cinquième niveau Facilitating bench-to-the bedside transition Optimising access to infrastructures and shared services 17/04/

4 Our partners Hospitals Research institutions University Regional institutions 4

5 Integrated Cancer Research in Bordeaux 5

6 BRIO at a glance projects 16 research teams 33 research staff directly funded by BRIO 150 research staff working on BRIO projects 7.5 million euros over 5 years 6

7 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research Implementation Strategy Breast Sarcoma PROGRAMMES 6 Research programmes Myeloid Leukemia Liver 7 Strategic axes Innovative Molecular Targets Geriatric Oncology STRATEGIC AXES 7

8 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research 6 integrated Research Programmes Breast cancer Sarcoma Myeloid Leukemia PROGRAMMES Breast Sarcoma Myeloid Leukemia Liver cancer Liver Innovative molecular targets Innovative Molecular Targets Geriatric Oncology Geriatric oncology 8 STRATEGIC AXES 8

9 Breast Cancer (Dr. H Bonnefoi) Implementation of new neo-adjuvant treatments in the Aquitaine and Limousin regions Translational research based on predictive markers, identification of new potential targets and use of new therapies Psychological distress evaluation of patients treated by neo-adjuvant therapies and identification of new interventional techniques 9

10 Innovative Molecular Targets Promote early clinical trials (Dr. A Italiano) Accelerate translational research through the identification of predictive biomarkers and resistance mechanisms to molecules under development Develop translational imaging, and more specifically the early prediction of treatments responses 10 10

11 Myeloid Leukemia (Dr. FX Mahon) Understand the mechanisms of formation of Chronic Myeloid Leukaemia (CML) to identify new therapeutic targets Understand the mechanisms of resistance linked to use of kinase inhibitors and identify alternative treatments Translational and clinical research on chronic and acute myeloid leukaemias to select appropriate treatments 11 11

12 Sarcoma (Dr. JM Coindre) Evaluate medical practices (diagnostic and treatment) and propose improvements via the French Sarcoma network Improve the efficacy and quality of locoregional treatments Improve the understanding of sarcoma biology in order to implement better predictive and diagnostic tools Promote clinical innovation and the development of adequate criterias to evaluate these new therapeutic tools 12 12

13 Geriatric Oncology (Dr. P Soubeyran) Optimise treatment selection through the use of optimal data including a geriatric evaluation Introduce adapted treatment rules, based on geriatric experience and allowing a more precise medical intervention Identify potential treatment solutions based on biological understanding of the disease through elderly-specific tumors (stem cells and immunology) Identification of and intervention on societal and psychological hurdles preventing an optimal treatment of elderly patients 13 13

14 Liver Cancer (Dr. J Rosenbaum) Characterise the mechanisms of liver cancer formation and identification of new therapeutic targets Improve Sorafenib efficacy via the characterisation of response markers Conduct clinical trials and explore innovative therapies Characterise non fibrotic hepatocellular carcinoma through epidemiological and biological studies Analyse medical practices and improve the understanding of risk factors Improve locoregional treatments for the treatment of liver cancer 14 14

15 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research 7 strategic axes PROGRAMMES Bioinformatics In-vivo research Outcome research Human and social sciences Breast Sarcoma Myeloid Leukemia Liver Databases Innovative Molecular Targets Personalised medicine Geriatric Oncology Basic research 15 STRATEGIC AXES 15 15

16 Knowledge dissemination and transfert Objectives : Research results dissemination to the relevant target populations Promote the interactions between groups Transfer results to the industry whenever applicable Research result dissemination Collaborations academics, industrial Researchers, students Health care professionals Patients General population Improve industrial collaborations Support start-ups Develop translational research Search fundings Improvement of patient care Better understanding of the disease, the treatments and the research 16 16

17 Collaborate with BRIO SIRIC What BRIO offers you: A network of multidisciplinary high-level researchers Access to clinicians and patients A SIRIC label, its visibility and a support for your grant requests Assistance to consolidation or transfer your research with academic or industrial partnerships Support to start-ups What BRIO is looking for: Partnerships related to cancer and specifically to the 6 programmes, seven axes and the knowledge dissemination programme Academic research in cancer biology, clinical, epidemiological, public health, human and social sciences Industrial research: biotech, pharma, diagnostics, biomarkers, medical devices, ICTs Collaborations with researchers, healthcare workers or patients associations Contact Dr Paolo Meoni - General Manager BRIO p.meoni@bordeaux.unicancer.fr Phone: (+33)